Trial Profile
Randomised Phase II Study of Neoadjuvant BIBW 2992 Versus Herceptin Versus Lapatinib in Her2 Positive Breast Cancer Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Lapatinib; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 21 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2011 Planned End Date changed from 1 Jul 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
- 01 Jun 2011 Planned end date changed from Sep 2011 to Jul 2011 as reported by ClinicalTrials.gov.